32 results about "Interfering virus" patented technology

In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV.

The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.

The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.

This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and / or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.

Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Cloned DI virus is then used in tests on mice and ferrets given a lethal challenge of wild-type influenza A virus. When cloned DI influenza A virus is co-administered with a lethal dose of virulent influenza A virus, mice are protected compared to a control of inactivated cloned DI influenza A virus. Mice which survived the administration of cloned DI influenza A virus and infective challenge virus are three weeks later still protected against lethal challenge with infective virus. Control mice which received only cloned DI influenza A virus and no lethal challenge are not protected three weeks later on lethal challenge with infective virus.

The invention relates to 'an expression vector of interfering viruses of barley yellow dwart viruses, a constructing method, and the application' and belongs to the technical field of biological engineering. The invention provides the expressing vector of interfering viruses of barley yellow dwart viruses which is characterized in that a skeleton carrier which is adopted is pMCG161, a sense strand of a coat protein gene of the barley yellow dwart viruses is inserted between two restriction sites of AscI and AvrII which are on the upstream portion of the pMCG161, and an antisense strand of the coat protein gene of the barley yellow dwart viruses is inserted between two restriction sites of SpeI and SgfI which are on the downstream portion of the pMCG161. The expression vector of interfering viruses of barley yellow dwart viruses GAV which is constructed by the invention is transferred into wheat through particle bombardment to obtain a transgene wheat variety which has resistance to the barley yellow dwart viruses GAV. The invention provides a breeding way with high efficiency and a new strategy.

The invention relates to a recombinant pseudorabies live vaccine for preventing African swine fever, and the preparation of the recombinant pseudorabies live vaccine. The constructed recombinant pseudorabies virus TIE1872V2Sag72 strain containing African swine fever virus CDV2 / P72 / BL602 genes, and a sacas9SgRNA sequence capable of knocking out a wild type P72 gene can express a recombinant CDV2 / P72 / BL602 protein antigen in a BHK cell strain, the expression amount is stable, and meanwhile, an in-vitro cell simulation experiment shows that the method can interfere virus replication. The recombinant strain pseudorabies virus strain is used as a production strain, the recombinant CDV2 / P72 / BL602 protein antigen obtained through suspension micro-carrier culture is used for preparing the live vaccine, and the live vaccine can prevent recently popular African swine fever viruses, and can be prepared into a spray drinking water form to reduce injection stress reaction.

The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to inhibition of flavivirus replication wherein the replication is affected by changing the normal interactions of the host cell protein TIAR or TIA-1.

Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Cloned DI virus is then used in tests on mice and ferrets given a lethal challange of wild-type influenza A virus. When cloned DI influenza A virus is co-administered with a lethal dose of virulent influenza A virus, mice areprotected compared to a control of inactivated cloned DI influenza A virus. Mice which survived the administration of cloned DI influenza A virus and infective challange virus are three weeks later still protected against lethal challange with infective virus. Control mice which received only cloned DI influenza A virus and no lethal challange are not protected three weeks later on lethal challange with infective virus. A therapeutic benefit of administering cloned DI influenza a virus is found when the administration takes place in less than 48 hours after challange with infective virus. Cloned DI influenza A virus of one subtype is found to act in vivo as an effective antiviral against the same or any other sub-type of influenza A virus. The antiviral effect has been found to have both a therapeutic and a prophylactic application against influenza A infection in humans, mammals and birds.

The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to inhibition of flavivirus replication wherein the replication is effected by changing the normal interactions of the host cell protein TIAR or TIA-1.

The invention relates to the technical field of chemical industry, in particular to a preparation method and application of micromolecule compound with HIV resisting activity. CyPA is able to combine with the Gag polymer protein in HIV-1. Silence or inhibit the activity of CypA with RNAi technology and disturb the replication of virus. The micromolecule compound in the invention refers to a CyPA inhibitor that has the effect of resisting HIV-1 virus. Besides, as the micromolecule compound is designed while aiming at cellular target, the invention is not easy to develop drug resistance, thus meeting the demands of lifetime medication for AIDS patients. Therefore, the micromolecule compound in the invention, which can be developed as a new type anti-AIDS drug, provides a new means for treating and curing AIDS.

The invention relates to the technical field of RNA (Ribonucleic Acid) interference, in particular to an RNA interference virus vector which interferes the expression of a target gene by expressing shRNAmir carried by a miR-AB framework based on human miR-30pril-miRNA. The miR-AB sequence is regulated and controlled by a plurality of eukaryotic promoters; the RNA interference virus vector traces cells subjected to RNA interference through fluorescent protein reporter molecules, or screens the cells subjected to RNA interference through antibiotics. According to the present invention, the miR-AB sequence in the RNA interference virus vector is regulated and controlled by a variety of eukaryotic promoters so as to easily achieve the application of the RNA interference virus vector in a variety of eukaryotic cells, and the virus vector can screen the cells subjected to RNA interference through antibiotics by depending on the Puromycin resistance, and can also trace the cells subjected to RNA interference by depending on the fluorescent protein reporter molecule; therefore, a plurality of target genes in the eukaryotic cell can be subjected to single-gene interference and multi-gene arbitrary combination interference at the same time in a multi-virus co-infection mode, so that the functions of the plurality of target genes in the eukaryotic cell are analyzed at the same time.

The present invention relates generally to an antibody that binds specifically to a neutralization epitope at the surface of papillomavirus (residues 36-49 of the minor capsid L2) that does not interfere with virus entry into endosomes and lysosomes. This antibody neutralizes infection of the virus in a dose dependent manner.